The difference your 2017 contribution made
A New Age in Anal Cancer Treatment
The promise of a cure got closer this year through the first advance in anal cancer treatment in 42 years. Working with a powerhouse research team at MD Anderson Cancer Center, we funded the first phase II immunotherapy trial ever conducted in anal cancer patients. The study achieved an unprecedented 24% response rate to the new immunotherapy, Nivolumab. Further, it was well tolerated with minimal side effects.
Fighting for Equitable Cancer Prevention
Cancer prevention for all
Another 3 countries expanded their female-only program to boys, bringing the total of countries vaccinating both genders to 15. In the UK, we rallied oncologists, medical experts and coalition members to change the JCVI's decision to not vaccinate boys. BBC covered the story, interviewing co-Founder Tristan Almada in a 12 minute live segment where he highlighted the clear flaws in the UK government's thinking. In November, we were pleased to see the committee acknowledged that their decision was based on outdated information. We expect the decision to be reversed in 2018 and UK boys to be finally be protected as well.
Racing To End Preventable Cancer
Advocacy in motion
Our NOMAN is an Island: Race To End HPV teams sped across the Mediterranean this summer with a record 8 crews rowing 200 miles each! The NOMAN campaign challenges individuals to extreme endurance events, raising awareness of the connection between HPV and cancer. This year, we raised over $600,000 and featured NOMAN's first all-female team. Watch highlights at www.nomancampaign.org.
A Cure for 5% of the World's Cancer
The Foundation supports novel and groundbreaking research into finding new treatments that benefits all HPV-related cancers. We are excited to have helped fund and develop the first ever trial to seek a therapy targeted to multiple HPV-related cancers simultaneously. The trial is currently accruing patients across the country at Dana-Farber Cancer Institute.
Recognized for contributions
In Boston, Co-Founder Justine Almada was honored as Mass General's annual One Hundred gala, an evening celebrating game-changers in the cancer community. The award stated that the Foundation has "an ambitious vision: develop new cures for and eliminate this cancer and its cause."
Our Peer to Peer Support Program continues to alleviate the isolation that many thrivers and caregivers encounter after diagnosis. We hear from thrivers that the information received from their peer mentors is often more helpful than what their medical team provides. Thank you to all the peer volunteers who have given their time and energy to this program.